Highmark Health to Evaluate Biocept Liquid Biopsy Platform

Highmark Health announced it will study the clinical and economic impact of Biocept’s Target Selector liquid biopsy in patients with non-small cell lung cancer. The 12-month evaluation is being conducted through Highmark’s Vital Innovation Program.

The results will be used to determine whether Target Selector can improve the molecular profiling rate of advanced NSCLC, Highmark said.

Source: https://www.genomeweb.com/molecular-diagnostics/highmark-health-evaluate-biocept-liquid-biopsy-platform?utm_source=Sailthru&utm_medium=email&utm_campaign=GWDN%20Thurs%20PM%20-%20Preheader%20Test%202018-08-23&utm_term=GWDN%20A/B%20Test